Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of class III antiarrhythmic agents.

L M Hondeghem1

  • 1Department of Pharmacology, HPC N.V., Oostende, Belgium.

Journal of Cardiovascular Pharmacology
|January 1, 1992
PubMed
Summary

Current antiarrhythmic drugs are less effective during rapid heart rates. Ideally, new agents should lengthen refractoriness during tachycardia (Class IIIA) to effectively treat arrhythmias.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oscillations of cardiac wave length and proarrhythmia.

Naunyn-Schmiedeberg's archives of pharmacology·2010
Same author

Ultrafast sodium channel block by dietary fish oil prevents dofetilide-induced ventricular arrhythmias in rabbit hearts.

American journal of physiology. Heart and circulatory physiology·2008
Same author

Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia.

Cardiovascular research·2001
Same author

Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.

Circulation·2001
Same author

Classification of antiarrhythmic agents and the two laws of pharmacology.

Cardiovascular research·2000
Same author

Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes.

Circulation·1995

Area of Science:

  • Cardiovascular Pharmacology
  • Cardiac Electrophysiology

Background:

  • Current antiarrhythmic drugs (Class IIIB) primarily lengthen action potential duration and refractory period during slow heart rates (bradycardia).
  • These agents lose efficacy during rapid heart rates (tachycardia), when antiarrhythmic intervention is most critical.

Purpose of the Study:

  • To propose an ideal characteristic for antiarrhythmic agents: lengthening refractoriness during tachycardia (Class IIIA) without affecting normal sinus beats.
  • To explore potential mechanisms for achieving Class IIIA effects.

Main Methods:

  • Conceptual analysis of antiarrhythmic drug mechanisms.
  • Identification of specific ion channel targets for Class IIIA activity.

Main Results:

  • Proposed Class IIIA agents should lengthen cardiac refractoriness relative to heart rate acceleration.
  • Three potential strategies for achieving Class IIIA effects were identified: upstroke-dependent activator of inward currents, use-dependent blocker of iTO in atria, and frequency-dependent blocker of late repolarizing currents (iKs) in ventricles.

Conclusions:

  • Development of Class IIIA antiarrhythmic agents represents a significant advancement in treating cardiac arrhythmias.
  • Targeting specific ion channel properties offers promising avenues for novel antiarrhythmic therapies effective during tachycardia.

Related Experiment Videos